Retinitis pigmentosa (RP) refers to a diverse group of progressive, hereditary diseases of the retina that lead to incurable blindness and affect two million people worldwide. Artificial photoreceptors constructed by gene delivery of light-activated channels or pumps ('optogenetic tools') to surviving cell types in the remaining retinal circuit has been shown to restore photosensitivity in animal models of RP at the level of the retina and cortex as well as behaviorally. The translational potential of this optogenetic approach has been evaluated using in vitro studies involving post-mortem human retinas. Here, we review recent developments in this expanding field and discuss the potential and limitations of optogenetic engineering for the treatment of RP.
POTENTIAL THERAPIES FOR RETINITIS PIGMENTOSA
Retinitis pigmentosa (RP) refers to a diverse group of progressive, hereditary diseases that lead to incurable blindness and affect two million people worldwide. RP commonly starts with night blindness in young adults, reflecting early degeneration of the highly sensitive rod photoreceptors. This is followed by a progressive decline in daylight central vision, due to loss of function of the less-sensitive cone photoreceptors. Mutations in more than 44 genes have been demonstrated in different forms of RP, 1,2 but in about 50% of cases the mutation has not yet been identified. Most of the known RP genes are expressed in rods and in such cases degeneration of cones is thought to be a secondary consequence of the death of the rods. 3, 4 There is no cure for RP, but several approaches for the treatment for particular forms of RP are in clinical trials, and others are likely to be introduced soon. 5 These approaches can be divided into three groups. First, gene supplementation 6 is conceptually simple and an attractive strategy if, as is the case in most recessive forms of RP, the disease is due to loss of function mutations. Progress in developing gene therapy for a form of Leber congenital amaurosis 7 caused by defects in the retinal pigment epithelium-specific gene, RPE65, has not only offered hope for patients with this disease, but has also boosted general confidence in gene therapy strategies for retinal disorders by demonstrating the safety and efficacy of adeno-associated viral (AAV) vectors, following intraocular administration in humans. [8] [9] [10] [11] As gene supplementation can only be applied when the cell type expressing the gene is still alive, early diagnosis and gene therapy in childhood may be necessary in the case of the most common rod-specific genes. Gene supplementation is more complicated in dominant forms of RP, 12 where the mutation induces a toxic pathway or in recessive RP, if the gene exceeds the packaging capacity of viral vectors that are suitable for use in humans. Nevertheless, when feasible, gene supplementation is the most obvious and probably the most effective way to restore function. A second approach is to slow the degeneration of photoreceptors and thus slow progression of the disease. [13] [14] [15] [16] [17] [18] Finally, there are a number of approaches that do not interfere with the intrinsic progression of disease but attempt to restore photosensitivity by creating new photosensors and coupling them to the remaining retinal circuitry. Patients who are legally blind are the key target population of these therapies. Three different strategies are being investigated: (1) the implantation of differentiated or undifferentiated photoreceptors, 19 (2) electronic retinal implants, [20] [21] [22] and (3) the subject of this review, so-called 'optogenetic' approaches, [23] [24] [25] which use genetically encoded light sensors to make cells light responsive. [26] [27] [28] The success of cellimplantation approaches depends on the formation of functional synapses between the implanted photoreceptors and endogenous bipolar cells, and on functional retinal pigment epithelium to supply photoreceptors with 11-cis-retinal. Electronic retinal implants and optogenetic approaches are similar in the sense that light is captured by an artificial photosensor and the current generated is used to stimulate retinal cells within the remaining retinal circuit. The key difference between these two techniques lies in the way in which the light-generated current stimulates cells. In the case of electronic implants, the current is distributed extracellularly and activates cells based on proximity and other physical parameters. Retinal implants validated the possibility to reactivate retinal circuits for restoring some visual perception. Some blind patients can read letters and even words. 22 In optogenetic approaches, a genetically encoded light sensor sits in the membrane of a retinal cell. The generated current flows across the cell membrane and thus activates or inactivates that particular cell. The critical aspect of optogenetic approaches is that the light sensors can be genetically targeted to different retinal cell types and, therefore, may provide artificially stimulated retinal activity that is closer to the normal activity of retinal circuits. Optogenetic approaches are only at the phase of pre-clinical trials.
This review focuses on advances in optogenetic stimulation of retinal circuits in animal models of RP, as well as in human retinal explants, and discusses the challenges of advancing the technology to clinical application.
CREATING ARTIFICIAL PHOTORECEPTORS IN THE REMAINING RETINAL CIRCUITRY
The key idea of optogenetic vision restoration is to target genetically encoded light sensors to strategically important retinal cell types, thus converting them into artificial photoreceptors.
If the artificial photoreceptors are connected to other cell types in the retinal circuit, light also modulates the activity of these cells. The challenge lies in choosing the right sensor and targeting strategy, so that the light-evoked retinal activity arising from artificial photoreceptors will be similar to the activity of normal retinas stimulated through their 'classical' photoreceptors. To understand the various strategies, it is necessary first to appreciate the retinal circuits of mammalian retinas that are conserved throughout the class.
THE MAMMALIAN RETINAL CIRCUIT
The mammalian retina can be viewed as a parallel image processor that acquires images with a mosaic of photoreceptors and then uses its internal neuronal circuits to compute more than a dozen neural representations of the visual world. 29, 30 These are sent to higher brain centres by the axons of different ganglion cell types. Cone photoreceptors, which are the light sensors during daylight, connect to 10 types of bipolar cells 31, 32 (Figure 1) . Half of the cone bipolar cells are activated by a decrease (OFF cells) and the other half by an increase (ON cells) in light intensity. The axon terminals of OFF and ON bipolar cells locate at different depths within the inner plexiform layer (IPL): OFF terminals in the distal part and ON terminals proximally. Order exists at an even finer scale: bipolar cell terminals occupy just one or a few of the 10 IPL strata.
Dendrites of more than a dozen types of ganglion cells also arborize in these strata and receive excitatory input from the bipolar cell terminals. The response polarity of a ganglion cell is determined by the type of bipolar cell providing the input: ON, OFF or ON-OFF. The photoreceptor-to-bipolar synapse in the outer plexiform layer is regulated by inhibitory horizontal cells. The excitatory synapse between bipolar and ganglion cells is modulated by inhibitory amacrine cells. These cells receive excitatory input from bipolar cells and feed-back or feed-forward to bipolar terminals and ganglion cell dendrites, respectively. Amacrine cells are extremely diverse with more than 30 morphological types described, which account for almost half of all retinal cell types. The function of most of them is unknown. Our current understanding is that each ganglion cell type incorporates a few bipolar and amacrine cell types in its local retinal circuit. These ganglion cell circuits are modular, because ganglion cells belonging to the same morphological and physiological type are arranged in a mosaic, covering the entire retina. Each ganglion cell type, together with its local circuit, extracts a particular feature from the visual scene.
In dim light conditions, images are captured by rod photoreceptors. Information from rods is transmitted to the axon terminals of ON and OFF cone bipolar cells via a small circuit. Rods connect to rod bipolar cells, which terminate in the most proximal part of the IPL (Figure 1b) . These bipolar cells are ON cells. Rod bipolar cells excite a type of interneuron, the AII amacrine cells, which provide inhibitory input to the terminals of OFF cone bipolar cells and are electrically coupled, and, therefore, provide excitatory input, to the axon terminals of ON cone bipolar cells. From cone bipolar cell axon terminals, the activity driven by rods follows the same route as the activity driven by cones. Alternative rod pathways have also been described. 33, 34 In primates, such as humans, the spatial layout of the retinal circuit organization described above is modified in a specialized retinal area, the fovea. The fovea is the place of high acuity vision and is, therefore, of central importance for routine human visual activities such as reading. While the basic connectivity of the fovea is similar to that of the primate periphery and of other mammalian retinas, there are some differences relevant for optogenetic strategies. First, the only cell type that is arranged in a mosaic in the fovea is the cone. All other cell types are packed closely together around the fovea in the foveal pit. Second, the fovea exhibits the lowest density of rods, which are completely absent from the centre of the fovea. Third, the convergence of foveal cones to ganglion cells is much lower than in the periphery, with some ganglion cell types connected to only a single cone.
OPTOGENETIC TOOLS AND STRATEGIES FOR THEIR USE IN RETINAL CELL TYPES
Optogenetics utilizes the ectopic expression of molecules to change the membrane potential of target cells following an increase in light intensity. There are two main types of optogenetic tools: those that Figure 1 Simplified schematic of the retinal circuit. Only excitatory pathways are shown. C, cone; R, rod; AII, AII amacrine cell; OPL, outer plexiform layer; IPL, inner plexiform layer.
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V Busskamp et al depolarize neurons and thus activate them, and others that hyperpolarize neurons and inactivate them. These tools are extensively reviewed elsewhere. [26] [27] [28] Here, we will discuss two microbial molecules: channelrhodopsin-2 from Chlamydomonas reinhardtii (ChR2), a light-gated cation channel that depolarizes ChR2-expressing cells upon light activation, 35, 36 and halorhodopsin from the archea Natronomonas pharaonis (NpHR) a light-activated chloride pump that hyperpolarizes NpHR-expressing cells, when these are illuminated. [37] [38] [39] Light stimulation of healthy retina leads to two different responses in retinal cells. Photoreceptors are hyperpolarized when light intensity increases. Horizontal cells, OFF bipolar cells, OFF amacrine cells and OFF ganglion cells, which are connected directly or indirectly by signconserving excitatory synapses to photoreceptors,, thus, also react by hyperpolarization.
NpHR would be the appropriate tool to be expressed in these OFF cells to mimic their normal activity. On the other hand, the synaptic connections between photoreceptors and ON bipolar cells are signinverting and, therefore, ON bipolar cells depolarize when light intensity increases.
ON amacrine (such as AII amacrine cells) and ON ganglion cells are connected by sign-conserving synapses to ON bipolar cells and, thus, as a result, they also depolarize. In this case, the normal light-evoked activity of ON cells would be mimicked by ChR2. For simplicity, ON-OFF cells are omitted from the discussion.
STRATEGIES FOR OPTOGENETIC RESTORATION OF VISION
There are (at least) five possible ways to reactivate retinal circuits in RP (Figure 2 ). Note that the state of retinal circuits in RP is different from that in normal retinas, [40] [41] [42] and we will compare the five approaches in the context of the state of retinal degeneration, the resulting retinal activity, and the applicability of optogenetics in patients.
One strategy is to express ChR2 using a strong ubiquitous promoter in many different types of retinal cells, that is, without targeting individual cell types. Following intravitreal injection of AAV-2 vectors, a range of ganglion cells and amacrine cells are transduced. Intravitreal injection of an AAV-2 vector carrying ChR2 in the rd1 mouse model of RP provided the first proof-of-concept that retinal function can be restored using optogenetics. The adult rd1 mouse lacks functional rod and cone photoreceptors and is thus a good model to test retinal photosensitivity following 'optogenetic therapy' . The study demonstrated ON responses in all recorded retinal ganglion cells and visually evoke potentials in the cortex. 23 Similar treatments were shown to evoke changes in behavior in rat models of RP. 43, 44 Furthermore, blind transgenic mice 45 and rats 46 have been generated that express ChR2 only in a subset of ganglion cells. The retinas of these transgenic animals regained light sensitivity and the rats showed visually guided behavior. Similarly, the broad expression of NpHR can lead to OFF responses and the combined expression of ChR2 and NpHR to ON and OFF responses 47 or, when differentially distributed within a cell, to center excitation and surround inhibition. 48 Light sensitive channels engineered from glutamate receptors were also shown to be effective in driving ganglion cell responses. 49 The other strategies, described below, differ from this first strategy in which the optogenetic sensor is expressed in a more restricted, strategically chosen cell class or type to provide more biologically relevant retinal stimulation. A second possible strategy is to refine the first approach and express different optogenetic tools in ON and OFF ganglion cells, such that ON ganglion cells express ChR2 and OFF ganglion cells NpHR. This would maintain their natural response polarity. This has not yet been achieved, most probably because of lack of knowledge about specific promoters for ON versus OFF ganglion cells. A third strategy is to express ChR2 in ON bipolar cells and NpHR in OFF bipolar cells to reactivate inhibitory modulation of ganglion cells by amacrine cells. In the healthy retina, amacrine cell activity is important for a variety of retinal functions, for example, for the detection of various components of image or eye motion. Using in vivo electroporation, 50 a method that is only feasible in experimental animals, ChR2 has been targeted to ON bipolar cells of rd1 mice. In these mice, the ON ganglion cells were activated by ChR2-expressing ON bipolar cells, and inhibited by amacrine cells, which were themselves excited by the light-sensitive ON bipolar cells. Notably, signs of inner retinal Optogenetic therapy V Busskamp et al computations, such as the temporal and spatial filtering has been observed, and only cells that had morphological signs (namely stratification) of ON ganglion cells responded to increases in light intensity. Light-evoked activity was measured in the cortex, and visually evoked behavior was documented. 25 Viral delivery of ChR2 to ON bipolar cells has recently been described. 51 Gene expression with current AAV serotypes and/or promoters is not yet efficient in human ON bipolar cells. 52 has not yet been achieved. A fifth current strategy exploits the finding in the rd1 mouse model of RP that the advent of a complete lack of rod-and cone-mediated light responses does not correspond to the advent of the death of rods and cones. Cone cell bodies remain alive long after the loss of photosensitivity. Their number decreases, but about 25% of cones still exist as long as 7 months after termination of rod-cone-mediated photosensitivity. 24 There is a similar dissociation of visual function and cone death in some human patients, 24 and post-mortem examination of the retinas of RP patients has revealed at least one row of foveal cones remaining in the fovea. 53, 54 Preservation of human cones has not been documented in the periphery. However, at later stages of RP, at least in rd1 mice, it is not easy to distinguish cone cell bodies from bipolar cells morphologically. The lack of a distinct outer nuclear layer or even the lack of opsin antibody staining does not necessarily indicate loss of cones. In situ hybridization with cone opsin, cone arrestin or other cone-specific mRNA may, in fact, be a better test for the presence of dormant cone cell bodies. When NpHR was expressed in light-insensitive cones in mouse models of RP, the relevant retinal ON and OFF ganglion cells were activated; light-evoked activity was measured in the cortex and visually evoked behavior was documented. 24 Importantly the result of sophisticated retinal processing, such as directional selective ganglion cell responses, has been measured in NpHR-driven retinas. One of the vectors used in this study was able to express NpHR in cones of human retinal explants, which led to hyperpolarization of human cones upon light stimulation. 24 CHOOSING AN OPTOGENETIC STRATEGY On the basis of our present knowledge, which is the best strategy that should perhaps be pursued in clinical trials? There is no simple answer to this question and, here, we discuss the advantages and limitations of each method. The first and perhaps most important consideration is the state of the retina in the patient to be treated. The neural circuit in the retina of patients with RP is different from that in normal retinas. 55 Our current understanding is that rods most often degenerate first, followed by cones. There are also a number of changes in the retinal circuit with time. Although we know a lot of details about the state of retinal cell types in the rd1 mouse model, human data is not easily available (but see refs. [53] [54] [55] , and just how far the lessons learned from mice will be applicable in patients is not yet clear.
There are considerable differences between patients in the progress of the disease and, for therapy, it is crucial to know which cell types are still alive and present at the time of intervention. Optical coherence tomography (OCT) can identify some of the cell classes still present in patients.
Correlation of the OCT images with clinical progression of the disease in genetically characterized cohorts of RP patients, and comparison of OCT images between different forms of RP, will provide useful guidelines for optogenetic approaches. One technical difficulty is that obtaining good quality OCT cross-sections depends on the ability to fixate the eye, which is not possible after loss of vision. As initial clinical trials of optogenetic therapy will most likely involve severely blind patients, it will be important to develop OCT technologies that do not require fixation or to block eye movement during screening.
Should we care about cell-type-specific targeting? If the goal is to mimic the normal processing of the retina, the answer is in the affirmative.' The more proximal to the photoreceptors we can stimulate the retina, the more normal retinal processing we should be able to invoke, provided that these circuits are still intact. What is not yet clear is whether other constraints could be present that do not allow cell-type-specific targeting, or whether it is really necessary, because our brain is so plastic that it can learn to process any type of stimulation. One practical constraint, for example, is the lack of promoters for ON versus OFF ganglion cells. Therefore, when targeting only the ganglion cells, there is currently no other option than to use ubiquitous promoters and turn all cells into either ON cells (with ChR2) or OFF cells (with NpHR), or a random mixture of both. As far as plasticity is concerned, results obtained with electronic implants predict that the brain can learn some basic features about the visual scene by retinotopic stimulation. However, the preservation of normal processing of the retina may have a major impact on the degree and/or quality of the visual functions regained. An example is the effect on eye motion. Our understanding is that most mammals have specialized ganglion cells that control the stabilization of gaze. ON directional selective ganglion cells respond to slow image motion and are believed to serve as a feedback signal for the vestibulo-ocular reflex and also to mediate components of the optokinetic reflex. There are three types of ON directional selective ganglion cells that preferentially respond to motion in three different axes, corresponding to the orientation of the three semicircular canals in the inner ear. The ON directional ganglion cell function depends on their interaction with a specialized amacrine cell in the IPL. Direct stimulation of ganglion cells would abolish directional selectivity and probably leave gaze stabilization impaired. On the other hand, cone-based stimulation may preserve directional selectivity and, therefore, restore some gaze control. Careful evaluation of eye movement before and after optogenetic treatment might be instructive when comparing different strategies.
We must also consider the anatomical layout of the different retinal cells. Cones, bipolar and amacrine cells have cellular compartments only within the eye, whereas ganglion cells send their axon terminals to various places in the brain. If inflammation is induced, despite preclinical safety tests, treating an eye condition is easier than treating several projection sites in the brain. Fusing the light sensor to dendritic localization signals could decrease, but may not abolish its presence in axons. Bipolar cells and cones in the periphery are vertically aligned, whereas ganglion cell axons run parallel to the image plane. If the expression of optogenetic tools is high in the ganglion cell axon, it might be excited directly, leading to loss of the retinotopic map. Here again dendritic localization of ChR2 could help prevent axonal excitation. The stimulation of the fovea presents a special problem. Because of the organization of bipolar and ganglion cells, which are pushed aside in the foveal pit, it is not possible to stimulate with a spatially continuous image. The spatial transformation of each light pixel to each foveal bipolar or ganglion cell is unknown and may vary from individual to individual. We argue, therefore, that in the fovea one should reactivate the remaining cones. The only elements that are laid down as a two-dimensional mosaic are the outer and, perhaps to a lesser degree, the inner segments of the cones. The cone cell bodies occupy several layers. If the outer and inner segments are lost, spatial resolution is limited by the diameter of the cone cell bodies. This leads to the interesting prediction that, until only one monolayer of cones is present, the resolution of the regained vision via NpHR expression in cones will not depend on the degree of cone loss: all the cone bodies are predicted to have a similar resolution, provided that cones on the top of each other sample visual 'pixels' close to each other.
The strategies that are practically feasible today are those using ubiquitous promoters to express optogenetic tools in ganglion cells and the targeting of remaining degenerate cones using photoreceptor-specific promoters. Currently available AAV serotypes in combination with ON bipolar cell-specific promoters may not be efficient enough for expressing enough light sensors in human bipolar cells to evoke substantial activity in retinal ganglion cells. However, this is a fast moving field and better vectors are not too far away. 51 AAV-based or other means of restricting expression of optogenetic tools to AII cells or ON-versus-OFF ganglion cells have not yet been reported.
POST-MORTEM HUMAN RETINA AS A MODEL SYSTEM
The usual requirements for the development of novel therapies include translation from small animal models, such as mice or rats, to safety tests in primates, followed by clinical trials. In the case of targeted optogenetic engineering, the specificity and efficacy of the promoter for the chosen cell class or type is of key importance. Testing many different promoters in vivo in primates is not possible. Recently an in vitro model system, a post-mortem human retina preparation in culture, has been developed 24, 52 that allows the investigation of gene expression from viral vectors. Although viral access to different retinal cell types is likely be different in vitro and in vivo, transducing human retina in culture allows one to make qualitative comparisons between the efficiency and specificity among different promoters. For example, high-level marker expression in the targeted cell type alone with one but not with another promoter would argue for continuing in vivo experiments with the former. Expression in multiple unwanted cell types would argue for more screening before in vivo safety experiments in primates. No intrinsic, rod-or cone-mediated, photosensitivity can be measured in these cultures, but NpHR targeted to human photoreceptors restored light responses in photoreceptor cells. It is not known yet whether bipolar or ganglion cells would also respond to light, but if they were to do so the human retinal culture model would open the way to study the functional architecture of human retinal circuits.
CRITICAL ISSUES TO CONSIDER IN OPTOGENETIC THERAPY Adaptation
The light intensities that reach our eye from the natural world can vary by more than 12 logarithmic units above the threshold of human vision. Rods and cones continuously adjust their sensitivity across 8-9 log units when reporting changes in intensities around the mean illumination. However, cells made light sensitive by optogenetic tools report intensity changes only in a fixed intensity window spanning not more than 2-3 log units. As a consequence, independent of the visual sensitivity of the artificial photoreceptor, an external device will be needed with an image sensor that can adapt to the mean illumination of the visual world, together with a visual stimulator that projects an image on the retina with a dynamic intensity range matching the sensitivity range of the artificial photoreceptor. When ganglion cells act as light sensors, this external device should perform not only adaptation and stimulation but also natural image-processing operations like contrast gain control and edge enhancement, normally performed by the retinal circuits.
Sensitivity
The light sensitivity of an optogenetically engineered cell depends on two factors: the number of optogenetic sensors in the membrane and the current produced by the capture of a photon by an individual sensor. 56 Currently, the sensitivity of optogenetically transduced cells is poor, cells providing photoresponses at high cone ranges. [23] [24] [25] The number of expressed sensors can be improved, for example, by using strong promoters, high AAV titers and optimal AAV serotypes for a given cell type. We are not aware, for instance, of an AAV serotype that transduces retinal bipolar cells efficiently. Furthermore, the very thick inner limiting membrane of the primate retina may act as a barrier for intravitreal gene delivery (at least for AAV serotype 2 (ref. 57) to ganglion cells outside the fovea, therefore, surgical removal of the inner limiting membrane may be needed. As far as increasing the sensitivity is concerned, in the case of light-gated channels (but not pumps), one could increase the membrane current produced by a captured photon by increasing the conductance of the channel. This has not been achieved yet to any significant degree. Another way to increase the sensitivity of the artificial photoreceptor cell is to increase the single channel opening time. 58 However, longer opening times also increase the period it takes to stop cell response after light offset. Therefore, this could lead to comet-like motion after-effects similar to a moving cursor on an old computer screen with a slow refresh rate. An excellent solution for the sensitivity-kinetics problem has been recently provided by Bamberg and colleagues. 59 The authors slightly increased the Ca permeability of ChR2 and therefore increased the number of Ca ions entering the cell-per-unit time, which in turn changes the surface potential of the cell and lower the spiking threshold of cells. This new form of ChR2 called CatCh has the same fast kinetics as ChR2, but the expressing cell is 70 times more sensitive to light. CatCh is, therefore, a promising candidate for stimulation of ganglion cells. The increased Ca permeability is also beneficial for stimulation of non-spiking cells such as retinal bipolar cells because the release of glutamate is triggered by Ca. How much sensitivity is really necessary if an external device is anyway required for adaptation? A practical definition of the minimum sensitivity offered by Degenaar et al. 56 is 'the amount of light that is allowed to radiate into the eye by regulatory agencies' . Note that this maximum-allowed radiation is wavelength dependent, in which more radiation is allowed at higher wavelengths. Therefore, red-shifted optogenetic sensors are preferred. Some patients with RP have photophobia for bright light; pre-screening these patients with light stimulation at the predicted optogenetic intensity range is important. The maximum sensitivity recommended could be that which is unable to produce retinal responses at the average indoor daylight intensity. Defining a maximum sensitivity would serve as a safety feature, if the regained excitation of the retina causes headache or dizziness. An increase in the sensitivity of all currently available tools is desirable. Finally, owing to convergence, it is to be expected that sensitivity will increase depending on the cell type stimulated with sensitivity increasing from ganglion cells to bipolar cells to cones.
The pupillary reflex
The size of the pupil controls the magnitude of light intensity in the retina. The pupillary reflex is partially functional in patients with RP, probably because the response in these patients is mediated by intrinsically photosensitive, melanopsin-containing ganglion cells. 60 
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The peak sensitivity of melanopsin at 480 nm is similar to the peak sensitivity of ChR2 and, therefore, one expects strong pupil constriction at this wavelength. Moving to red-shifted sensors will thus increase the amount of light falling on to the retina owing to lessefficient pupillary constriction.
Color vision
Current optogenetic approaches use a single sensor for light sensing, except for two reports in which ChR2 and NpHR were coexpressed. 47, 48 The human retina has three types of cones, which together with their visual circuitries mediate color perception. It would be reasonable to introduce spectrally shifted light sensors into the remaining cones. Recent advances in understanding and controlling color vision in primates 61 as well as in in vitro post-mortem human retina preparation offers possibilities for investigations in this direction.
Dynamic range
The state of the optogenetically engineered cell may have a major impact on the dynamic range of its gained photosensitivity. We will explain this problem in the context of restoring photosensitivity to cones. In RP patients the dark voltage of cones is unknown and may vary by gene defect and with disease progression. If the dark voltage is very negative, further hyperpolarization with NpHR may lead to a very limited decrease in the amount of neurotransmitter released and, therefore, to changes of only few ganglion cells spikes. Increasing the dark voltage using ChR2 may increase significantly the range of neurotransmitter release that can be modulated by light. Forms of ChR2 that can be locked in the open state from seconds to minutes with a blue background illumination could fine-tune the 'dark' voltage of cells whereas NpHR stimulation with red light could modulate the cone voltage. The simultaneous expression of NpHR and ChR2 together with push-pull stimulation with red-blue light therefore could improve cone stimulation. Furthermore, mimicking the dynamics of primate photoreceptors by implementing, digitally, a temporal filter between the light signal entering the stimulation goggle and the light used for stimulation might lead to cone responses that match normal responses.
Eye motion
Loss of central vision is often associated with increased eye motion. Large amplitude eye motion would disable simple stimulation paradigms through an external device. It is possible that regained retinal photosensitivity will reduce eye motion, but it would be advantageous when choosing patients for therapy to take into account eye motion and the potential problems this may introduce.
Patients with remaining central vision RP is a progressive disease and many patients have useful residual central visual function for most of their life. 62 Initially, optogenetic therapy will likely focus on patients who are legally blind, with minimal or no measurable central vision. However, when safety has been confirmed, the development of new tools may allow optogenetic treatment in patients with some remaining vision. Especially exciting tools would be new NpHR derivates that can be excited at nearinfrared wavelengths. NpHR expression is not toxic to wild-type mouse photoreceptors and results in a gain of function: 24 the native cone opsins remain active and extra photosensitivity is induced at longer wavelengths. Such approaches with potential near-infrared sensors may allow vision enhancement in patients without perturbing their remaining visual capacity.
Immune responses
A key but unknown variable with optogenetic therapies is the extent to which optogenetic tools expressed from AAVs might induce immune reactions. The eye and the brain are immune-protected areas and it is encouraging that, despite the use of optogenetic tools by a number of research groups in the eyes and brains of primates and rodents, no strong immune responses have been reported. Note that at least one potential light sensor, human melanopsin, would probably not lead to an immune response. If the slow kinetics of melanopsin-induced responses could be engineered to be faster, this tool could be highly valuable for immunological reasons. 63 The use of AAV-2 has been shown to be safe for human patients. 64 However, the more potent serotypes, for example, AAV-7 and AAV-8, have not yet been tested in the clinic. Preclinical trials should address carefully the immunogenic potential of the different optogenetic tools in combination with AAV serotypes. Gene expression from AAVs has been reported to last for at least 1.5 years in humans, 64 but it is not yet known how long the sensitivity of optogenetic sensors will persist. Therefore, re-injection of AAVs 65 expressing optogenetic sensors should also be tested in preclinical trials. Human immune reactions can be different from those of other primates, and the safety of the expression of optogenetic sensors in therapies will be a major factor in their potential use.
SUMMARY
The development of molecular tools to make neurons light-sensitive, and of methods to target gene expression to selective retinal cell types has made it possible to reactivate light-insensitive retinas in rodent models of RP. Further developments for enhancing their clinical applications include more sensitive artificial photoreceptors that are at least as fast as normal photoreceptors, sensors that work at nearinfrared wavelengths, highly effective dendritic localization signals, AAV serotypes (natural or artificial) able to transduce bipolar cells effectively, short promoters that restrict expression to a variety of cell types when used in AAVs or alternatively AAVs that enter only specific cell types, 66 and light-stimulation goggles with image-processing capabilities. The combination of optogenetic therapies with methods that slow down photoreceptor degeneration, or with the implantation of stem cell/photoreceptor precursors if the retinal cycle regenerating the photopigment is missing, may lead to new ways of enhancing the capabilities of all three of these approaches. RP is just one disease group for which making cells light-sensitive may help to restore some visual function. In the future, other diseases, such as the final, blinding stages of age-related macular degeneration, may also benefit from these developments.
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